Tradestie Institutional Equity Comparison Engine
CASI vs SRZN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SRZN Overall Edge
SRZN Captures Institutional Edge (3โ0 Pillars ยท 6โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Surrozen, Inc. Common (SRZN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, CASI trades at N/M Forward P/E with -333.1% operating margin (-60.5% YoY revenue) versus SRZN at N/M Forward P/E and -485.4% operating margin (+408.6% YoY). In options structure, CASI sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against SRZN sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
CASI N/M vs SRZN N/M Fwd P/E
Growth & Margin Winner
SRZN
Op Margin -333.1% vs -485.4% ยท YoY -60.5% vs +408.6%
Momentum & Technical Winner
SRZN
1Y -91.4% vs +110.8% ยท 52W Pos 0% vs 63%
Options & Structure Winner
SRZN
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (13th %ile IV)
CASI
NASDAQ
CASI Pharmaceuticals, Inc. Ordinary Shares
Pharmaceutical Preparations
$0.21
-74.06% 1D
Market Cap
$12.4M
1M Return
-78.83%
1Y Return
-91.43%
Forward P/E
N/M
Unified AI Score
44.7 / 100
HOLD
Tech 40.0
Fund 44.0
Flow 50.0
Mom 44.0
SRZN
NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$28.46
-7.21% 1D
Market Cap
$642.7M
1M Return
+10.52%
1Y Return
+110.81%
Forward P/E
N/M
Unified AI Score
36.0 / 100
SELL
Tech 15.0
Fund 42.0
Flow 65.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CASI -91.43%
SRZN +110.81%
Spread: +182.93 pp (SRZN Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
CASI TTM Op. Margin: -333.1%
SRZN TTM Op. Margin: -485.4%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CASI vs SRZN. Trailing 12-month operating profitability (CASI -333.1% vs SRZN -485.4%) and valuation multiples (CASI N/M vs SRZN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CASI | SRZN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $12.4M | $642.7M | Larger Scale | SRZN |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -60.5% | +408.6% | Higher Growth | SRZN |
| Operating Margin (TTM) Profitability | -333.1% | -485.4% | Higher Margin | CASI |
| Net Profit Margin Profitability | -184.0% | 0.0% | Higher Margin | SRZN |
| Return on Equity (ROE) Capital Efficiency | -1094.5% | -62.8% | Higher ROE | SRZN |
| 52-Week Range Position Momentum | 0% ($0โ$3) | 63% ($13โ$38) | Stronger Trend | SRZN |
| Beta / 30D Volatility Risk Regime | 0.95ฮฒ ยท 240% Vol | 1.29ฮฒ ยท 73% Vol | Lower Realized Risk | SRZN |
| Unified Institutional Score Composite Signal | 44.7 / 100 (HOLD) | 36.0 / 100 (SELL) | Higher Composite | CASI |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CASI vs SRZN Buy Guide
CASI
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
SRZN
CONSOLIDATION
41d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
13th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CASI nor SRZN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.